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ABSTRACT
Background : Kawasaki disease is one of the leading causes of acquired heart disease
in children. It is an acute self-limited vasculitis that predominantly affects infants
and children younger than 5 years of age. These patients present with nonspecific
symptoms, such as fever and lymphadenopathy, making the diagnosis challenging. This
disease can have serious and potentially fatal outcomes, and prompt recognition of this
disease is vital to the patient’s outcome. We present a complete review of the disease,
including the epidemiology, pathophysiology, diagnosis and management of acute
Kawasaki disease, the natural history of this disease, and follow up of these patients as
they transition into the adult cardiology practice.
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Methods: Our systematic review information was collected from articles retrieved from
PubMed library. Keywords that were used included; Kawasaki disease, coronary artery
disease, coronary artery aneurysm, pediatric coronary artery disease, epidemiology of
Kawasaki disease and treatment of Kawasaki disease. We included only relevant to the
topic articles. No exclusion criteria were applied.
Conclusions: Kawasaki disease incidence tends to be increasing over the last decade
in the United States. Seasonality of the disease has been described in Japan. It is a
mysterious disease with unknown etiology, however, multiple hypotheses have been
proposed and tested to explain the pathophysiology. As this disease has an associated
high morbidity and mortality, prompt recognition and management are important to
the patient’s overall prognosis and survival.
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INTRODUCTION
Kawasaki disease (KD), previously known as
mucocutaneous lymph node syndrome, is an acute
self-limited vasculitis that predominantly affects
infants and children younger than 5 years of age.
The disease was first described in Japan by Tomisaku
Kawasaki in 1967 and is known to occur in both
Americas, Europe, and Asia; Japan has recorded the
highest incidence and prevalence of the disease
across the globe.1,2,3 Patients present with nonspecific
symptoms, such as fever and lymphadenopathy,
making the diagnosis challenging.3 Kawasaki disease
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can have serious and potentially fatal outcomes,
and prompt recognition of this disease is vital to the
patient’s outcome.
METHODS
Our systematic review information was collected from
articles retrieved from PubMed library. Keywords
that were used included: Kawasaki disease, coronary
artery disease, coronary artery aneurysm, pediatric
coronary artery disease, epidemiology of Kawasaki
disease and treatment of Kawasaki disease. We
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included only relevant to the topic articles. No
exclusion criteria were applied. Twenty-eight articles
were selected as a source of information.

polymerase chain reaction, and increased levels
of IL-1 pathway proteins in plasma support the
activation of the interleukin (IL)-1 pathway in
Kawasaki disease.13

EPIDEMIOLOGY

Also in KD, as in giant cell arteritis,14 two dominant
cytokine clusters are recognized: the IL-6/T helper
(Th)-17 axis and the IL-12/interferon gamma axis.
IL-6, in combination with transforming growth
factor beta (TGFb), polarizes naïve T cells toward a
Th-17 phenotype, resulting in these cells invading
the vessel wall and elaborating a proinflammatory
cytokine profile.15,16

The prevalence of KD is reportedly the highest in
Japan and in those with Japanese descent.4 In 2012,
data from Japan revealed that the annual incidence
was 264.8 cases per 100,000 children aged 0-4 years
per year.5 Reported data from US has been based on
hospital discharge data; it appears that in 2000, 4248
hospitalizations in patients with KD were noted and
there has not been a significant increase in the last
decade.6 In regard to gender, data from the United
States reports an incidence of boys: girls at 1.5:1,
suggesting that this disease is more common in
males.5 Interestingly, there are also seems to be an
association with seasonality. Japan and Korea have
both reported peaks in January and July, with a nadir
in October.7-9 In contrast, KD occurs more commonly
during the winter and early spring months in the
United States.10 The fatality rate from KD in Japan has
been reported as high as 0.08% and all deaths from
KD are a result of cardiac sequelae.3
PATHOPHYSIOLOGY
The etiology of this mysterious disease is unknown
and there have been multiple attempts to explain
this disease by an infection and toxins, however,
trials have failed to show an association. As young
infants rarely have been reported to have this disease,
there is a theory that there is some protection from
maternal antibodies.3
On a microscopic level, in acute KD it has been shown
that both the innate and adaptive immune systems
are involved. Neutrophils are
among the first responders to
invade the arterial wall and
are followed by CD8+ T cells,
dendritic cells, and monocyte/
macrophages.11,12 Increased
transcript abundance for IL-1
related genes by microarray
and quantitative real-time
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DIAGNOSIS
With the unknown and unidentified etiology of
Kawasaki disease, the diagnosis remains based on
careful clinical evaluation of patients with suspected
KD.17 The nonspecific symptoms and signs of
KD are shared with multiple other diseases and
conditions, thus, one should be very thorough and
systematic to rule out a broad differential diagnosis
(Table 1).18 The 2004 American Heart Association
(AHA) guidelines and the fifth edition of the Japan
Diagnostic Guidelines (JDG) both list six principal
clinical features for KD diagnosis.3,17 While the AHA
guidelines considers having a prolonged fever
(more than five days) an essential element for the
diagnosis of KD, the JDG gives the prolonged fever
equal weight to other clinical features.3,17 Along
with prolonged fever, patients who meet complete
(typical) AHA KD diagnosis criteria should also have
four of the following principal clinical features: 1)
bilateral conjunctival injection, 2) changes of the
mucous membranes (chapped lips, strawberry
tongue, or injected pharynx, 3) polymorphous skin
rash, 4) changes in the extremities (swelling of hands
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and feet, erythema, or periungal desquamation), 5)
cervical lymphadenopathy (usually unilateral, and it
is the least common finding).3
Not all patients with suspected KD develop five
principal clinical features. There is a portion of KD
patients that develop four or less of the principal
symptoms and signs.4 These subsets of patients
have been described under the term of atypical (or
incomplete) KD.3 Atypical KD has been described
mostly in ages less than 6 months and older than 10
years.19 These patients have a higher incidence rate
of coronary artery lesions, the major complication
of KD.19 As atypical KD cases do not fulfill the
criteria for complete KD diagnosis, the evaluating
clinician should look for other supportive clinical
and laboratory supplementary findings of KD. The
supplementary findings are detailed by systems
in Table 2.3,17 With the suspicion of KD (prolonged
fever) and incomplete fulfillment of clinical criteria
(presence of 2 or 3 other principal clinical features),
patients should undergo continuous clinical

reassessment to look for further development of
the missing principal features. Simultaneously,
laboratory evaluation should take place to look
for supplementary laboratory evidence (Table 2).
If the patient meets incomplete criteria for KD,
echocardiographic evaluation is warranted.3
MANAGEMENT OF ACUTE KD
The main rationale behind administering the acute
treatment for KD cases is to prevent coronary artery
lesions and decrease its burdens.3 Optimally, and
to have the best response, acute treatment should
be instituted in the first ten days of illness.3 The
most effective regimen that has been described
consists of high dosage (2g/kg) of intravenous
immunoglobulin (IVIG) infusion.3 Along with IVIG
infusion, a high dosage of aspirin (80 to 100 mg/
kg/day) should be administered to achieve antiinflammatory and antiplatelet effect.3 IVIG should be
infused slowly over eight to twelve hours. Infusion
may be repeated if fever
persists 36-48 hours after the
first infusion.3 High dosage
aspirin is recommended during
the period that the patient
is symptomatic (usually the
first 48 hours).3,17 Antiplatelet
aspirin dosage (5 mg/kg/day) is
indicated until long-term follow
up is completed.3,17 Other
regimens of acute treatment
for KD, most commonly
conjunctional use of steroids,
have been described in cases of
resistant KD cases.20,21
The ultimate management of
patients with KD also requires
an initial echocardiographic
evaluation of their coronary
arteries along with complete
echocardiographic study.3 This
baseline echocardiographic
coronary evaluation helps
stratify the coronary risk
for patients with KD, and it
determines the antithrombotic
treatment and follow-up
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schedule they should follow.7 Patients with no
coronary artery lesions (Z Scores < 2) should be on
low dosage aspirin (antiplatelet therapy) for four
to six weeks, with repeated echocardiographic
evaluations in two weeks and six to eight weeks after
the onset of illness.3 Patients with higher coronary
risks with dilated coronary artery diameters (Z
scores > 2.5) will undergo a lifelong follow up for
surveillance of worsening aneurysms and tailoring
of antithrombotic treatment based on their coronary
risk.22,23
NATURAL HISTORY AND CARDIAC FINDINGS

a combination of antiplatelet and anticoagulant
therapy based on risk stratification (see below). It
should be noted, however, that these patients who
develop acute thrombosis should not be treated
as if this was due to plaque rupture; therefore,
thrombolytics have been suggested and therapy
with aspirin, heparin, and glycoprotein IIb/IIIa
inhibitors should be utilized. Catheter intervention
with balloon angioplasty, rotational ablation, and
stent placement can be utilized; however, if this
is not successful and the patient has severe left
ventricular dysfunction or vessels with multiple,
ostial, or long-segment lesions, then coronary artery
bypass surgery is recommended.3

Cardiac findings that have been reported in
the literature include coronary aneurysms,
myocarditis, mitral regurgitation from papillary
muscle dysfunction, myocardial infarction, or
valvulitis. These abnormalities can be identified by
echocardiography, magnetic resonance imaging
(MRI)/magnetic resonance angiogram (MRA), and/or
cardiac angiography.3

Patients with KD tend to have higher adverse
cardiac risk profiles, with higher blood pressures
and derangements in lipid profiles.28 The population
of children with KD reaching adulthood is growing.
Hence, risk stratification and follow up of these
patients are vital for long-term management.
Listed below is a consensus by experts in regard to
classifying these patients and management.3

With a specific focus on coronary artery aneurysms,
it is noted that the morphology of coronary arteries
changes dynamically with time in KD. Aneurysms
may increase in size in the first two months of illness;
resolution generally occurs in one to two years in 5067% of patients after disease onset.24,25 The resolution
of the aneurysm depends on multiple factors such
as the age of onset of disease, initial morphology,
location and size of aneurysm. For example, the
smaller the size of aneurysm, the greater the
likelihood of resolution. The worst consequences
appear to occur in giant aneurysms (maximum
diameter >8mm).26 In giant aneurysms, there can
be stenotic lesions on either side of the aneurysmal
sac due to marked proliferation of the myointima,
which can result in high morbidity and mortality.25
Interestingly, the coronary artery aneurysms
that undergo resolution have an abnormal
histopathology; specifically, they have a decreased
vascular response to isosorbide dinitrate, indicating
endothelial dysfunction.27

Risk Level I: echocardiography does not show any
coronary artery changes at any stage of the illness
• Pharmacological therapy: none beyond 1st 6-8
weeks
• Physical activity: no restrictions beyond 1st 6-8
weeks
• Follow up and Diagnostic Testing: cardiovascular
risk assessment, counseling at 5-year intervals
• Invasive testing: not recommended

Therapeutic regimens to prevent thrombosis
of coronary arteries in these patients include
antiplatelet therapy with aspirin, +/- clopidogrel
or dipyridamole, anticoagulation with warfarin, or
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Risk Level II: echocardiography shows transient
coronary artery ectasia or dilatation that is known to
disappear within the first 6-8 weeks
• Pharmacological therapy: none beyond 1st 6-8
weeks
• Physical activity: no restrictions beyond 1st 6-8
weeks
• Follow up and Diagnostic Testing: cardiovascular
risk assessment, counseling at 3-5 year intervals
• Invasive testing: not recommended
Risk Level III: echocardiography or angiography
shows isolated (solitary) small to medium (3-6 mm or
Z score between 3 and 7) coronary artery aneurysm
in >1 coronary arteries
• Pharmacological therapy: low dose aspirin
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(3-5 mg/kg aspirin/d), at least until aneurysm
regression is documented
Physical activity:
• <11 years of age: no restrictions beyond
1st 6-8 weeks
• 11-20 years of age: physical activity
guided by stress test, evaluation of
myocardial perfusion scan; contact or
high-impact sports discouraged for
patients taking antiplatelet agents
• Follow up and Diagnostic Testing:
annual cardiology follow up with
echocardiogram and EKG, combined
with cardiovascular risk assessment
counseling; biennial stress test/evaluation
of myocardial perfusion scan
• Invasive testing: angiography if
noninvasive test suggests ischemia

•

Risk Level IV: >1 large coronary artery aneurysm (>6
mm) and coronary artery that contains multiple
(segmented) or complex aneurysms without
obstruction
• Pharmacological therapy: long-term antiplatelet
therapy + warfarin with INR goal 2-2.5 OR low
molecular weight heparin (target antiXa level of
0.5-1.0) should be combined in giant aneurysms
• Physical activity: avoid contact or high-impact
sports due to higher risk of bleeding; other
restrictions are guided by stress test/evaluation
of myocardial perfusion scan outcome
• Follow up and Diagnostic Testing: biannual follow
up with echocardiogram and EKG; annual stress
test/evaluation of myocardial perfusion scan
• Invasive testing: first angiography at 6-12 months
or sooner if clinically indicated; repeated if
noninvasive testing, clinical/laboratory findings
suggest ischemia
Risk Level V: angiography confirms the presence of
coronary artery obstruction
• Pharmacological therapy: long-term low-dose
aspirin; if presence of giant aneurysm, add
warfarin or low molecular weight heparin;
consider beta blockers to reduce myocardial
oxygen consumption
• Physical activity: avoid contact or high-impact
sports due to higher risk of bleeding; other
restrictions are guided by stress test/evaluation
of myocardial perfusion scan outcome
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•

•

Follow Up and Diagnostic Testing: biannual
follow up with echocardiogram and EKG; annual
stress test/evaluation of myocardial perfusion
scan
Invasive testing: angiography recommended to
address therapeutic options

CASE
We present a case of a 32 year old male with a
history of Kawasaki disease with known coronary
artery aneurysms, hypertension and hyperlipidemia,
taking rivaroxaban, managed at an outside facility
who was referred after a positive exercise stress test
ordered for exertional chest pain and dyspnea. He
was found to have marked ST segment depressions,
mainly in the inferior leads, when walking on the
treadmill. Subsequent left heart catheterization
revealed large aneurysms in the left anterior
descending and right coronary artery with critical
stenosis (Figures A & B). The patient was referred for
cardiac bypass surgery for further management.

FIGURE A: Mid RCA with thrombosed aneurysm

FIGURE B: Aneurysm of the proximal left anterior
descending artery
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SUMMARY
KD is one of the leading causes of acquired cardiac
disease in children, noted to be higher in incidence
in Japan and the United States. As with our patient,
coronary aneurysms have been known to be a
common sequela of this disease. Therefore, prompt
recognition and treatment during the acute phase
of KD is important. For those patients with residual
coronary disease, prevention and management of
myocardial ischemia and dysfunction are paramount.
AUTHOR AFFILIATIONS

REFERENCES

™

Expanding Knowledge to Improve Rural Health.

9.

11.
12.

1. Kawasaki T. Acute febrile mucocutaneous
syndrome with lymphoid involvement with
specific desquamation of the fingers and toes.
Jpn J Allergol. 1967;16:178-222.
2. Makino N, Nakamura Y, Yashiro M, et al.
Descriptive epidemiology of Kawasaki disease in
Japan, 2011-2012: from the results of the 22nd
nationwide survey. J Epidemiol. 2015;25:239-45.
3. Newburger JW, Takahashi M, Gerber MA,
et al. Diagnosis, treatment, and long-term
management of Kawasaki disease: a statement
for health professionals from the committee
of rheumatic fever, endocarditis and Kawasaki
disease, Council on cardiovascular disease in the
young, American Heart Association. Circulation.
2004;110:2747-71.
4. Yanagawa H, Nakamura Y, Yashiro M, et al.
Incidence survey of Kawasaki disease in 1997 and
1998 in Japan. Pediatrics. 2001;107(3). Available
at: www.pediatrics.org/cgi/content/full/107/3/
e33
5. Holman RC, Curns AT, Belay ED, Steiner
CA, Schonberger LB. Kawasaki syndrome
hospitalizations in the United States, 1997 and
2000. Pediatrics. 2003;112:495–501.
6. Maddox RA, Person MK, Joseph LI, et al.
Monitoring the occurrence of Kawasaki syndrome
in the United States. Proceedings of the Eleventh

MEDICINE

8.

10.

1. Marshall University Joan C. Edwards School of
Medicine, Huntington, West Virginia

MARSHALL JOURNAL OF

7.

13.

14.

15.
16.

17.

18.
19.

International Kawasaki Disease Symposium; 3-6
February 2015; Honolulu, Hawaii. Abstract O.03,
p. 28.
Uehara R, Belay ED. Epidemiology of Kawasaki
disease in Asia, Europe, and the United States. J
Epidemiol. 2012;22(2):79-85.
Makino N, Nakamura Y, Yashiro M, et al.
Descriptive epidemiology of Kawasaki disease in
Japan, 2011-2012: from the results of the 22nd
nationwide survey. J Epidemiol. 2015;25:239-45.
Park YW, Han JW, Hong YM, et al. Epidemiologic
features of Kawasaki disease in Korea, 20062008. Pediatr Int. 2011;53:36-9.
10. Saundankar J, Yim D, Itotoh B, et al. The
epidemiology and clinical features of Kawasaki
disease in Australia. Pediatrics. 2014;133:e100914.
Fujiwara H, Hamashima Y. Pathology of the heart
in Kawasaki disease. Pediatrics. 1978;61:100–107.
Takahashi K, Oharaseki T, Naoe S, Wakayama
M, Yokouchi Y. Neutrophilic involvement in the
damage to coronary arteries in acute stage of
Kawasaki disease. Pediatr Int. 2005;47: 305–10.
Brown TJ, Crawford SE, Cornwall ML, Garcia F,
Shulman ST, Rowley AH. CD8 T lymphocytes
and macrophages infiltrate coronary artery
aneurysms in acute Kawasaki disease. J Infect
Dis. 2001;184: 940–3.
Hoang LT, Shimizu C, Ling L, et al. Global gene
expression profiling identifies new therapeutic
targets in acute Kawasaki disease. Genome Med.
2014;6:541.
Weyand CM, Goronzy JJ. Immune mechanisms
in medium and large-vessel vasculitis. Nat Rev
Rheumatol. 2013;9:731–40.
Rasouli M, Heidari B, Kalani M. Downregulation
of Th17 cells and the related cytokines with
treatment in Kawasaki disease. Immunol Lett.
2014;162:269–75.
Ayusawa M, Sonobe T, Uemura S, et al. Revision
of diagnostic guidelines for Kawasaki disease
(the 5th revised edition). Pediatrics international:
official journal of the Japan Pediatric Society.
2005;47(2):232-234.
Cox JR, Sallis RE. Recognition of kawasaki
disease. The Permanente journal. 2009;13(1):5761.
Nakamura Y, Yashiro M, Uehara R, et al.
Epidemiologic features of Kawasaki disease
in Japan: results of the 2009-2010 nationwide

mds.marshall.edu/mjm
© 2022 Marshall Journal of Medicine

Marshall Journal of Medicine
Volume 4 Issue 1

survey. Journal of epidemiology. 2012;22(3):216221.
Kobayashi T, Saji T, Otani T, et al. Efficacy
of immunoglobulin plus prednisolone for
prevention of coronary artery abnormalities
in severe Kawasaki disease (RAISE study): a
randomised, open-label, blinded-endpoints trial.
Lancet (London, England). 2012;379(9826):16131620.
Kobayashi T, Kobayashi T, Morikawa A, et
al. Efficacy of intravenous immunoglobulin
combined with prednisolone following
resistance to initial intravenous immunoglobulin
treatment of acute Kawasaki disease. The Journal
of pediatrics. 2013;163(2):521-526.
Newburger JW, Takahashi M, Burns JC. Kawasaki
Disease. Journal of the American College of
Cardiology. 2016;67(14):1738-1749.
Manlhiot C, Millar K, Golding F, McCrindle BW.
Improved classification of coronary artery
abnormalities based only on coronary artery
z-scores after Kawasaki disease. Pediatric
cardiology. 2010;31(2):242-249.
Takahashi M, Mason W, Lewis AB. Regression of
coronary aneurysms in patients with Kawasaki
syndrome. Circulation. 1987;75(2):387-94.
Kato H, Sugimura T, Akagi T, Sato N, Hashino
K, Maeno Y, et al. Long-term consequences
of Kawasaki disease. A 10- to 21-year
follow-up study of 594 patients. Circulation.
1996;94(6):1379-85.
Tatara K, Kusakawa S. Long-term prognosis of
giant coronary aneurysm in Kawasaki disease: an
angiographic study. J Pediatr. 1987;111(5):70510.
Sugimura T, Kato H, Inoue O, Takagi J, Fukuda T,
Sato N. Vasodilatory response of the coronary
arteries after Kawasaki disease: evaluation by
intracoronary injection of isosorbide dinitrate. J
Pediatr. 1992;121(5 Pt 1):684-688.
Silva AA, Maeno Y, Hashmi A, Smallhorn JF,
Silverman ED, McCrindle BW. Cardiovascular risk
factors after Kawasaki disease: a case-control
study. J Pediatr. 2001;138(3):400-5.

20.

21.

22.
23.

24.
25.

26.

27.

28.

MARSHALL JOURNAL OF

MEDICINE
™

Expanding Knowledge to Improve Rural Health.

mds.marshall.edu/mjm
© 2022 Marshall Journal of Medicine

Marshall Journal of Medicine
Volume 4 Issue 1

